Unmet needs in ANCA-associated vasculitis: Physicians’ and patients’ perspectives
暂无分享,去创建一个
A. Vaglio | L. Quartuccio | G. Emmi | F. Mescia | E. Treppo | F. Alberici | G. Del Frate | Livio Urso | G. del Frate | Federica Mescia
[1] B. Tampe,et al. Tailored Use of Avacopan in a Case With Refractory Antineutrophil Cytoplasmic Antibody-Associated Renal Vasculitis and Concominant Complement System Activation , 2022, Kidney international reports.
[2] M. Konig,et al. Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2022, Arthritis & rheumatology.
[3] A. Ekici,et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus , 2022, Nature Medicine.
[4] L. Mouthon,et al. Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2022, JAMA network open.
[5] S. Cong,et al. Long-Term Prognostic Factors in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A 15-Year Multicenter Retrospective Study , 2022, Frontiers in Immunology.
[6] C. Klersy,et al. Factors influencing patient-reported outcomes in ANCA-associated vasculitis: correlates of the Patient Global Assessment. , 2022, Seminars in arthritis and rheumatism.
[7] P. Merkel,et al. AB0626 Prevalence of Frailty in an Internet-Based Cohort with a Self-Reported Diagnosis of Vasculitis – The VascStrong Study , 2022, Annals of the Rheumatic Diseases.
[8] K. Thomas,et al. AB0633 Health-Related Quality of Life in ANCA Vasculitides and Rheumatoid Arthritis patients: a cross-sectional comparative study , 2022, Annals of the Rheumatic Diseases.
[9] S. Sartorelli,et al. AB0627 Evaluation of internal consistency, feasibility, and reliability of the Italian version of ANCA-associated vasculitis patient-reported outcome (AAV-PRO_ita) questionnaire: preliminary results from a multicenter study on a large cohort of Italian patients , 2022, Annals of the Rheumatic Diseases.
[10] L. Mouthon,et al. Remission and Low Disease Activity in Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual , 2022, Arthritis care & research.
[11] I. Gunnarsson,et al. Pentraxin-3 – a potential biomarker in ANCA-associated vasculitis , 2022, Scandinavian journal of rheumatology.
[12] J. Robson,et al. ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives , 2022, Journal of inflammation research.
[13] A. Chaudhry,et al. Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE) , 2022, Arthritis Research & Therapy.
[14] A. Gaffo,et al. Clinical Features of ANCA-Associated Vasculitis in African American Patients in the United States , 2022, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[15] B. Bonnotte,et al. Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry , 2022, RMD Open.
[16] G. Guyatt,et al. Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review , 2022, BMJ Open.
[17] P. Merkel,et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis , 2022, Annals of the Rheumatic Diseases.
[18] P. Merkel,et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis , 2022, Annals of the Rheumatic Diseases.
[19] P. Merkel,et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis , 2022, Annals of the Rheumatic Diseases.
[20] T. Rabelink,et al. Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2021, Kidney international reports.
[21] S. Shinjo,et al. Mortality predictors in ANCA-associated vasculitis , 2021, Medicine.
[22] J. Robson,et al. Patient reported outcomes in systemic vasculitis , 2021, Current opinion in rheumatology.
[23] J. Yazdany,et al. The Relationship Between Electronic Health Record System and Performance on Quality Measures in the American College of Rheumatology’s Rheumatology Informatics System for Effectiveness (RISE) Registry: Observational Study , 2021, JMIR medical informatics.
[24] M. Schönermark,et al. Hohe Krankheitslast bei Patienten mit ANCA-assoziierter Vaskulitis , 2021, Der Internist.
[25] W. Ng,et al. Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research , 2021, Nature Reviews Rheumatology.
[26] Lorena M. Salto,et al. ANCA-associated vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California , 2021, Clinical Rheumatology.
[27] M. Gatto,et al. IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis. , 2021, Journal of autoimmunity.
[28] G. Guyatt,et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2021, Arthritis & rheumatology.
[29] E. Daugas,et al. ANCA-Negative Pauci-immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[30] K. Hiromura,et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. , 2021, JAMA.
[31] K. Polkinghorne,et al. The impact of antineutrophil cytoplasmic antibody‐associated vasculitis on employment and work disability in an Australian population , 2021, International journal of rheumatic diseases.
[32] Jean-Paul Makhzoum,et al. Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives , 2021, International journal of rheumatology.
[33] A. Meara,et al. ANCA-Associated Vasculitis: An Update , 2021, Journal of clinical medicine.
[34] P. Merkel,et al. Avacopan for the Treatment of ANCA-Associated Vasculitis. , 2021, The New England journal of medicine.
[35] C. Selmi,et al. The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies. , 2021, Autoimmunity reviews.
[36] Nathan P. Dawkins,et al. Management of fatigue with physical activity and behavioural change support in vasculitis: a feasibility study. , 2020, Rheumatology.
[37] J. V. van Dongen,et al. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients , 2020, Frontiers in Immunology.
[38] C. Roubille,et al. Comorbidities and health-related quality of life in Patients with Antineutrophil Cytoplasmic Antibody (ANCA) - associated vasculitis. , 2020, Autoimmunity reviews.
[39] C. Selmi,et al. Frailty in Rheumatic Diseases , 2020, Frontiers in Immunology.
[40] J. C. Tervaert,et al. Vasculitis patient journey: a scoping review of patient experiences with vasculitis , 2020, Clinical Rheumatology.
[41] P. Merkel,et al. Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review of randomized trials. , 2020, Seminars in arthritis and rheumatism.
[42] R. Rudin,et al. Digital health technologies: opportunities and challenges in rheumatology , 2020, Nature Reviews Rheumatology.
[43] F. Valent,et al. Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases , 2020, Internal and Emergency Medicine.
[44] Lindsay Lally,et al. Localized Granulomatous with Polyangiitis (GPA): Varied Clinical Presentations and Update on Treatment , 2020, Current Allergy and Asthma Reports.
[45] S. Zheng,et al. Pentraxin 3: A promising therapeutic target for autoimmune diseases. , 2020, Autoimmunity reviews.
[46] Johannes Leierer,et al. Comorbidities in ANCA-associated vasculitis , 2020, Rheumatology.
[47] Qi Zhao. Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date , 2020, BioDrugs.
[48] N. Zhang,et al. Reduced activated regulatory T cells and imbalance of Th17/activated Treg cells marks renal involvement in ANCA-associated vasculitis. , 2019, Molecular immunology.
[49] X. Mariette,et al. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy. , 2019, Rheumatology.
[50] A. Diepstra,et al. CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients , 2019, Front. Immunol..
[51] R. Hunter,et al. Long-term outcomes in elderly patients with ANCA-associated vasculitis , 2019, Rheumatology.
[52] L. Graça,et al. T follicular helper cells and T follicular regulatory cells in rheumatic diseases , 2019, Nature Reviews Rheumatology.
[53] R. B. Henderson,et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study , 2019, Arthritis & Rheumatology.
[54] A. Caristan,et al. Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2019, Arthritis & rheumatology.
[55] Courtney A. Roberts,et al. Economic and objective burden of caregiving on informal caregivers of patients with systemic vasculitis. , 2019, Musculoskeletal care.
[56] D. Misra,et al. Is granulomatosis with polyangiitis in Asia different from the West? , 2018, International journal of rheumatic diseases.
[57] J. Levy,et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis , 2018, Rheumatology.
[58] N. Basu,et al. The Longitudinal Course of Fatigue in Anca Associated Vasculitis. , 2019, The Journal of rheumatology.
[59] P. Garred,et al. Pentraxins in Complement Activation and Regulation , 2018, Front. Immunol..
[60] P. Ravaud,et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides , 2018, Annals of the rheumatic diseases.
[61] V. Ravindran,et al. Digital health: a new dimension in rheumatology patient care , 2018, Rheumatology International.
[62] P. Merkel,et al. Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire , 2018, Annals of the rheumatic diseases.
[63] M. Singhal,et al. Clinical features and long‐term outcomes of 105 granulomatosis with polyangiitis patients: A single center experience from north India , 2017, International journal of rheumatic diseases.
[64] C. Salvarani,et al. Unmet Needs in the Pathogenesis and Treatment of Vasculitides , 2018, Clinical Reviews in Allergy & Immunology.
[65] N. Alcocer-Castillejos,et al. Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis , 2018, Rheumatology International.
[66] K. Kishibe,et al. A novel strategy with combined assays for detection of anti-neutrophil cytoplasmic antibody (ANCA) in clinically ANCA-negative granulomatosis with polyangiitis patients. , 2017, Auris, nasus, larynx.
[67] N. Belfeki,et al. Granulomatosis with polyangiitis in Tunisia. , 2017, Reumatismo.
[68] Kenneth G. C. Smith,et al. Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis. , 2017, The Journal of allergy and clinical immunology.
[69] L. Mouthon,et al. Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. , 2016, Clinical and experimental rheumatology.
[70] M. Petri,et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis , 2016, Annals of the rheumatic diseases.
[71] R. Pereira,et al. Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis. , 2017, Revista brasileira de reumatologia.
[72] N. Basu,et al. Physical Fatigue, Fitness, and Muscle Function in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2016, Arthritis care & research.
[73] J. C. Cohen Tervaert,et al. Editorial: Can an Increase in Antineutrophil Cytoplasmic Autoantibody Titer Predict Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis? , 2016, Arthritis & rheumatology.
[74] P. Merkel,et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis , 2016, Annals of the rheumatic diseases.
[75] R. Hubbard,et al. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. , 2016, Rheumatology.
[76] C. Pusey,et al. Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series , 2016, Rheumatology.
[77] C. Feighery,et al. Urinary Soluble CD163 in Active Renal Vasculitis. , 2016, Journal of the American Society of Nephrology : JASN.
[78] A. Mantovani,et al. Detection of Anti-Pentraxin-3 Autoantibodies in ANCA-Associated Vasculitis , 2016, PloS one.
[79] P. Merkel,et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type , 2015, Annals of the rheumatic diseases.
[80] U. Maggiore,et al. Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[81] Kenneth G. C. Smith,et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. , 2015, Rheumatology.
[82] V. Tesar,et al. Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab , 2015, American Journal of Nephrology.
[83] Yichun Hu,et al. Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis , 2015, Annals of the rheumatic diseases.
[84] P. Emery,et al. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions , 2015, Annals of the rheumatic diseases.
[85] P. Ravaud,et al. Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty‐Five Years or Older: Results of a Multicenter, Open‐Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide–Based Induction Therapy , 2015, Arthritis & rheumatology.
[86] N. Basu,et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[87] P. van Paassen,et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. , 2015, Journal of the American Society of Nephrology : JASN.
[88] P. Cacoub,et al. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. , 2014, Autoimmunity reviews.
[89] Yichun Hu,et al. Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. , 2014, Seminars in arthritis and rheumatism.
[90] D. Reid,et al. Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. , 2014, Rheumatology.
[91] S. Ito,et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study , 2014, Arthritis Research & Therapy.
[92] N. Basu,et al. Autoantibodies to hLAMP-2 in ANCA-negative pauci-immune focal necrotizing GN. , 2014, Journal of the American Society of Nephrology : JASN.
[93] Min Chen,et al. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[94] A. V. van Beek,et al. Androgen deficiency in male patients diagnosed with ANCA-associated vasculitis: a cause of fatigue and reduced health-related quality of life? , 2013, Arthritis Research & Therapy.
[95] E. Lee,et al. The clinicopathologic characteristics of granulomatosis with polyangiitis (Wegener’s): a retrospective study of 45 patients in Korea , 2013, Modern rheumatology.
[96] G. Waiter,et al. Fatigue-related brain white matter changes in granulomatosis with polyangiitis. , 2013, Rheumatology.
[97] P. Heeringa,et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. , 2013, The Journal of clinical investigation.
[98] Kenneth G. C. Smith,et al. Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis , 2013, Kidney international.
[99] Sandrine Katsahian,et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis , 2012, Annals of the rheumatic diseases.
[100] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.
[101] Yeong-Wook Song,et al. ANCA-associated vasculitis: report from Korea , 2013, Clinical and Experimental Nephrology.
[102] T. Dörner,et al. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity , 2012, Arthritis Research & Therapy.
[103] P. Merkel,et al. IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis , 2011, Proceedings of the National Academy of Sciences.
[104] F. Arnett,et al. DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. , 2011, Journal of the American Society of Nephrology : JASN.
[105] J. Bena,et al. Pilot study to assess the frequency of fibromyalgia, depression, and sleep disorders in patients with granulomatosis with polyangiitis (Wegener's) , 2011, Arthritis care & research.
[106] R. Bertina,et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. , 2010, Journal of the American Society of Nephrology : JASN.
[107] P. Merkel,et al. Patient‐reported outcome assessment in vasculitis may provide important data and a unique perspective , 2010, Arthritis care & research.
[108] P. Merkel,et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.
[109] P. van Paassen,et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. , 2010, The New England journal of medicine.
[110] S. Ndongo,et al. [Systemic vasculitis: study of 27 cases in Senegal]. , 2010, Medecine tropicale : revue du Corps de sante colonial.
[111] M. Gobbi,et al. Regulation of leukocyte recruitment by the long pentraxin PTX3 , 2010, Nature Immunology.
[112] Katrien G Luijkx,et al. Toward a conceptual definition of frail community dwelling older people. , 2010, Nursing outlook.
[113] V. Tesar,et al. Reduced number of endothelial progenitor cells is predictive of early relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis. , 2009, Rheumatology.
[114] F. Luft,et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.
[115] David Steven Scott,et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.
[116] E. Reinhold-Keller,et al. Cyclophosphamid oral vs. Bolus bei Wegener-Granulomatose und anderen ANCA-assoziierten Vaskulitiden , 2008, Zeitschrift für Rheumatologie.
[117] M. Haubitz,et al. Diagnostic role of endothelial microparticles in vasculitis. , 2008, Rheumatology.
[118] N. Chen,et al. Analyzing Fatal Cases of Chinese Patients with Primary Antineutrophil Cytoplasmic Antibodies-Associated Renal Vasculitis: A 10-Year Retrospective Study , 2008, Kidney and Blood Pressure Research.
[119] Min Chen,et al. Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Older Patients , 2008, Medicine.
[120] L. Onetti,et al. [Wegener's granulomatosis: its prevalence in a ten-year period in the rheumatology service of the Clinic Hospital, Cordoba, Argentina]. , 2006, Revista de la Facultad de Ciencias Medicas.
[121] Ying Zhang,et al. Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. , 2005, Kidney international.
[122] G. EduardoWainstein,et al. Clinical features of Wegener granulomatosis and microscopic polyangiitis in Chilean patients , 2005 .
[123] C. Kallenberg,et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[124] D. Scott,et al. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. , 2003, Arthritis and rheumatism.
[125] M. Haubitz,et al. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis , 2003, The Lancet.
[126] P. Pfitzenmeyer,et al. Vasculitis in the Very Elderly , 2002, Gerontology.
[127] C. Gordon,et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.
[128] C. Hack,et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. , 1989, The Journal of clinical investigation.
[129] R. Falk,et al. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. , 1988, The New England journal of medicine.
[130] A. Fauci,et al. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. , 1971, The New England journal of medicine.